Horizon Therapeutics Public Stock Forecast, Price & News

Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

Is Horizon Therapeutics Public a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 1 sell rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public or view top-rated stocks.

How has Horizon Therapeutics Public's stock been impacted by Coronavirus?

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HZNP stock has increased by 240.1% and is now trading at $103.76.
View which stocks have been most impacted by COVID-19.

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 5,940,000 shares, an increase of 78.9% from the October 14th total of 3,320,000 shares. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is presently 4.7 days. Approximately 2.7% of the shares of the stock are short sold.
View Horizon Therapeutics Public's Short Interest.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Horizon Therapeutics Public.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.54 by $0.21. The biopharmaceutical company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $979.49 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 26.85% and a net margin of 18.66%. The business's revenue for the quarter was up 62.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.74 earnings per share.
View Horizon Therapeutics Public's earnings history.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public updated its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.16 billion-$3.21 billion, compared to the consensus revenue estimate of $3.12 billion.

What price target have analysts set for HZNP?

10 analysts have issued 1-year price targets for Horizon Therapeutics Public's stock. Their forecasts range from $100.00 to $168.00. On average, they anticipate Horizon Therapeutics Public's share price to reach $126.67 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public or view top-rated stocks among Wall Street analysts.

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:

• Timothy P. Walbert, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• Paul W. Hoelscher, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
• Jeffrey W. Sherman, Chief Medical Officer & Executive Vice President (LinkedIn Profile)
• Jeffrey D. Kent, Executive VP-Medical Affairs & Outcomes Research
• Elizabeth H.Z. Thompson, Executive Vice President-Research & Development (LinkedIn Profile)

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

Who are some of Horizon Therapeutics Public's key competitors?

Some companies that are related to Horizon Therapeutics Public include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of HZNP's competitors.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.96%), Paulson & CO. Inc. (2.72%), Janus Henderson Group PLC (2.67%), Bank of New York Mellon Corp (1.67%), Voya Investment Management LLC (1.47%) and Renaissance Technologies LLC (1.43%). Company insiders that own Horizon Therapeutics Public stock include Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends for Horizon Therapeutics Public.

Which institutional investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., William Blair Investment Management LLC, Renaissance Technologies LLC, Point72 Asset Management L.P., BlackRock Inc., Eagle Asset Management Inc., Thornburg Investment Management Inc., and Wellington Management Group LLP. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, Vikram Karnani, and William F Daniel.
View insider buying and selling activity for Horizon Therapeutics Public or view top insider-selling stocks.

Which institutional investors are buying Horizon Therapeutics Public stock?

HZNP stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Morgan Stanley, American Century Companies Inc., TimesSquare Capital Management LLC, Assenagon Asset Management S.A., Liontrust Investment Partners LLP, Lord Abbett & CO. LLC, and Janus Henderson Group PLC.
View insider buying and selling activity for Horizon Therapeutics Public or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $103.76.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public has a market capitalization of $23.53 billion and generates $2.20 billion in revenue each year. The biopharmaceutical company earns $389.80 million in net income (profit) each year or $2.32 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

Horizon Therapeutics Public employs 1,395 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

Where are Horizon Therapeutics Public's headquarters?

Horizon Therapeutics Public is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at [email protected], or via fax at 224-383-3001.